{
    "clinical_study": {
        "@rank": "6682", 
        "arm_group": [
            {
                "arm_group_label": "AYX1 Injection 660 mg / 6 mL", 
                "arm_group_type": "Experimental", 
                "description": "Single Intrathecal (spinal) administration of AYX1 Injection (660 mg in 6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery"
            }, 
            {
                "arm_group_label": "Placebo Injection 6 mL", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single Intrathecal (spinal) administration of Placebo Injection (6 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery"
            }, 
            {
                "arm_group_label": "AYX1 Injection 1100 mg / 10 mL", 
                "arm_group_type": "Experimental", 
                "description": "Single Intrathecal (spinal) administration of AYX1 Injection (1100 mg in 10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery"
            }, 
            {
                "arm_group_label": "Placebo Injection 10 mL", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single Intrathecal (spinal) administration of Placebo Injection (10 mL) just prior to intrathecal administration of spinal anesthetic for knee surgery"
            }
        ], 
        "brief_summary": {
            "textblock": "The objectives of this study are to evaluate the safety and analgesic efficacy of a single\n      preoperative intrathecal administration of AYX1 Injection at two dose/volume levels."
        }, 
        "brief_title": "Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Postsurgical Pain", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Scheduled to undergo primary unilateral TKA for painful osteoarthritis without\n             congenital knee pathology\n\n          -  American Society of Anesthesiologists Physical Status Classification System \u2264 3\n\n          -  Medically stable as determined by the Investigator based on pre-study medical\n             history, physical/neurological examination, clinical laboratory tests, and 12-lead\n             electrocardiogram (ECG) findings\n\n          -  Body Mass Index of 18-40 kg/m2\n\n          -  Stable medical regimen for at least 1 month before randomization\n\n          -  Able to read and understand study instructions in English, and willing and able to\n             comply with all study procedures\n\n        Exclusion Criteria:\n\n          -  More than 2 other current focal areas of pain, none greater in intensity than the\n             target knee and no other active chronic pain conditions that would compromise\n             operative knee pain evaluation\n\n          -  Inflammatory arthridities (e.g., rheumatoid arthritis, lupus, ankylosing spondylitis,\n             psoriatic arthritis), with the exception of clinically stable/non-active gout that\n             does not affect the knee and does not interfere with walking\n\n          -  Operative arthroscopy in the surgical knee in the last 4 months (except for meniscal\n             repair which will be no shorter than 6 months before randomization), or other prior\n             surgery in either knee in the last 12 months, except for diagnostic arthroscopy\n\n          -  Planned use of any of the following for TKA: general anesthesia using potent\n             inhalational agents, peripheral nerve block (i.e., femoral nerve block), neuroaxial\n             (intrathecal or epidural) opioids postoperatively, or knee capsule injections\n\n          -  Received aspirin within 1 week of randomization, or any nonsteroidal\n             anti-inflammatory drug (NSAID) within 5 half-lives prior to randomization, or planned\n             use of NSAIDS post-operatively through Day 28\n\n          -  Use of more than 20 mg per day (on average) of oral morphine or its equivalent within\n             1 month prior to randomization\n\n          -  Use of adjuvant analgesics for chronic pain control (e.g., gabapentin, pregabalin)\n             within 2 weeks prior to randomization or planned use post-operatively through Day 28\n\n          -  Daily use of benzodiazepines in the 3 months prior to randomization (unless used for\n             sleep and dosage will be consistent after surgery)\n\n          -  Use of systemic corticosteroids (does not include inhaled steroids) within 3 months\n             or intra-articular steroid injections within 1 month prior to randomization, or\n             planned use of either post-operatively through Day 28\n\n          -  Treatment with immunosuppressives, antipsychotics, anticholinergics, or\n             anticonvulsants within 1 month of randomization, with the exception of aspirin for\n             cardiac prophylaxis (as long as discontinued within 1 week of randomization)\n\n          -  Current neurologic disorder, which could confound the assessment of pain (e.g.,\n             Parkinson's, Multiple Sclerosis)\n\n          -  Current active depression symptoms\n\n          -  Has had a change in dose or regimen of SSRIs or SNRIs for depression within 1 month\n             of randomization\n\n          -  Mini Mental State Exam score < 24 at Screening\n\n          -  Severe chronic obstructive or restrictive pulmonary disease, current diagnosis of\n             obstructive sleep apnea documented by a sleep laboratory study, or current home use\n             of continuous positive airway pressure (CPAP) or bi-level positive airway pressure\n             (BIPAP)\n\n          -  Current evidence of alcohol abuse or history of alcohol-related complications within\n             1 year of randomization including, but not limited to, alcoholic withdrawal seizures,\n             hallucinations, delirium tremens or detoxification treatment\n\n          -  Known or suspected history of illicit drug abuse within 1 year before randomization,\n             current or planned use of medical marijuana, or history of opioid dependence within 2\n             years before randomization\n\n          -  Any malignancy within the past year, with the exception of basal cell carcinoma or\n             uncomplicated or stable skin cancers documented to not require further or immediate\n             treatment\n\n          -  Women who are pregnant or nursing\n\n          -  Previous participation in any study involving AYX1 Injection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02081703", 
            "org_study_id": "ADYX-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "AYX1 Injection 660 mg / 6 mL", 
                "description": "6 mL solution for intrathecal injection with 660 mg of AYX1", 
                "intervention_name": "AYX1 Injection 660 mg / 6 mL", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AYX1 Injection 1100 mg / 10 mL", 
                "description": "10 mL solution for intrathecal injection with 1100 mg of AYX1", 
                "intervention_name": "AYX1 Injection 1100 mg / 10 mL", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Injection 6 mL", 
                "description": "6 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)", 
                "intervention_name": "Placebo Injection 6 mL", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Injection 10 mL", 
                "description": "10 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)", 
                "intervention_name": "Placebo Injection 10 mL", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Postsurgical pain", 
            "Total knee arthroplasty", 
            "Total knee replacement"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sheffield", 
                        "country": "United States", 
                        "state": "Alabama"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2 Study to Evaluate the Safety & Efficacy of Two Dose/Volume Levels of a Single Intrathecal Preoperative Administration of AYX1 Injection in Patients Undergoing Unilateral Total Knee Arthroplasty", 
        "other_outcome": {
            "description": "Percentage of subjects achieving 90 degrees of active knee flexion in the operative knee at Discharge through Day 42", 
            "measure": "Percentage of subjects achieving 90 degrees of knee flexion", 
            "safety_issue": "No", 
            "time_frame": "Hospital discharge to Day 42"
        }, 
        "overall_contact": {
            "email": "khebert@adynxx.com", 
            "last_name": "Kimberly Hebert", 
            "phone": "415-512-7740", 
            "phone_ext": "204"
        }, 
        "overall_official": {
            "affiliation": "Adynxx, Inc.", 
            "last_name": "Donald C Manning, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Mean pain rating on the Numerical Rating Scale (NRS) with walking during the 5 meter walk test during the inpatient stay (0-48 hours)", 
                "measure": "Pain with walking during 5 meter walk test", 
                "safety_issue": "No", 
                "time_frame": "0-48 hours after surgery"
            }, 
            {
                "description": "Mean pain rating on the Numerical Rating Scale (NRS) with walking during the 15 meter walk test during the outpatient period up to Day 28", 
                "measure": "Pain with walking during 15 meter walk test", 
                "safety_issue": "No", 
                "time_frame": "Hospital Discharge to Day 28"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02081703"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Mean pain rating on the Numerical Rating Scale (NRS) for 45 degrees passive knee flexion during the inpatient stay", 
                "measure": "Pain with 45 degrees of knee flexion", 
                "safety_issue": "No", 
                "time_frame": "0-48 hours after surgery"
            }, 
            {
                "description": "Mean pain rating on the Numerical Rating Scale (NRS) for 90 degrees passive knee flexion during the outpatient period to Day 28", 
                "measure": "Pain with 90 degrees of knee flexion", 
                "safety_issue": "No", 
                "time_frame": "Hospital discharge to Day 28"
            }, 
            {
                "measure": "Total use of opioid medications (morphine equivalents) during hospital stay", 
                "safety_issue": "No", 
                "time_frame": "0-48 hours after surgery"
            }, 
            {
                "measure": "Total use of opioid medications (morphine equivalents) post-discharge to Day 28", 
                "safety_issue": "No", 
                "time_frame": "Hospital Discharge to Day 28"
            }
        ], 
        "source": "Adynxx, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Adynxx, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}